CRASH 3 – clinical randomisation of an antifibrinolytic in significant head injury

The CRASH-3 trial is being conducted to assess the effect of tranexamic acid on risk of death or disability in patients with Traumatic Brain Injury (TBI), which can cause bleeding in the brain. If left to continue, it can create pressure that can lead to further damage that will result in death or permanent disability. By conducting this trial, important evidence is being collected to help determine if tranexamic acid is an effective treatment for patients with TBI. Read more at http://crash3.lshtm.ac.ukCRASH-3 tranexamic acid

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s